An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
Authors
Keywords
Neuroblastoma, <sup>131</sup>I-MIBG, Targeted radiotherapy, PARP-1, DNA damage
Journal
BMC CANCER
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-08-11
DOI
10.1186/s12885-016-2656-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
- (2015) J. Bendell et al. ANNALS OF ONCOLOGY
- Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
- (2015) S G DuBois et al. BRITISH JOURNAL OF CANCER
- PARP Inhibitor PJ34 Suppresses Osteogenic Differentiation in Mouse Mesenchymal Stem Cells by Modulating BMP-2 Signaling Pathway
- (2015) Yuta Kishi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma
- (2015) Erika A. Newman et al. MOLECULAR CANCER RESEARCH
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upfront treatment of high-risk neuroblastoma with a combination of131I-MIBG and topotecan
- (2015) Kathelijne C.J.M. Kraal et al. PEDIATRIC BLOOD & CANCER
- Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself
- (2015) Cian M. McCrudden et al. PLoS One
- In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio
- (2015) Cihan Gani et al. RADIOTHERAPY AND ONCOLOGY
- A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
- (2013) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma
- (2013) Jayne S. Wilson et al. EUROPEAN JOURNAL OF CANCER
- Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
- (2013) Hae-June Lee et al. MOLECULAR CANCER THERAPEUTICS
- New Approaches of PARP-1 Inhibitors in Human Lung Cancer Cells and Cancer Stem-Like Cells by Some Selected Anthraquinone-Derived Small Molecules
- (2013) Yu-Ru Lee et al. PLoS One
- PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells
- (2013) Payel Chatterjee et al. PLoS One
- Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
- (2012) Hsiao-Ching Chuang et al. BREAST CANCER RESEARCH AND TREATMENT
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Promising Therapeutic Targets in Neuroblastoma
- (2012) K. K. Matthay et al. CLINICAL CANCER RESEARCH
- Structural Basis of Selective Inhibition of Human Tankyrases
- (2012) Mohit Narwal et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Toxicity of 131I-Metaiodobenzylguanidine/Topotecan Combination Therapy to Cells and Xenografts That Express the Noradrenaline Transporter
- (2012) A. G. McCluskey et al. JOURNAL OF NUCLEAR MEDICINE
- Dose Escalation Study of No-Carrier-Added 131I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial
- (2012) K. K. Matthay et al. JOURNAL OF NUCLEAR MEDICINE
- Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity
- (2012) Letizia Porcelli et al. Molecular Oncology
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
- (2011) Jens Samol et al. INVESTIGATIONAL NEW DRUGS
- Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft
- (2011) J. M. Senra et al. MOLECULAR CANCER THERAPEUTICS
- Treatment of advanced neuroblastoma in children over 1 year of age: The critical role of 131I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen
- (2011) Stefano Mastrangelo et al. PEDIATRIC BLOOD & CANCER
- Preclinical Assessment of Strategies for Enhancement of Metaiodobenzylguanidine Therapy of Neuroendocrine Tumors
- (2011) Rob J. Mairs et al. SEMINARS IN NUCLEAR MEDICINE
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Sensitization to Radiation and Alkylating Agents by Inhibitors of Poly(ADP-ribose) Polymerase Is Enhanced in Cells Deficient in DNA Double-Strand Break Repair
- (2010) D. A. Loser et al. MOLECULAR CANCER THERAPEUTICS
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?
- (2009) M. Ali et al. CLINICAL CANCER RESEARCH
- Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
- (2009) R. A. Daniel et al. CLINICAL CANCER RESEARCH
- Iodine-131—Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I Study
- (2009) Katherine K. Matthay et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90
- (2009) F. A. Dungey et al. MOLECULAR CANCER THERAPEUTICS
- Neuroblastoma: Biology and staging
- (2009) Sabine Mueller et al. Current Oncology Reports
- Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
- (2008) R. Plummer et al. CLINICAL CANCER RESEARCH
- Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential
- (2008) Fiona A. Dungey et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now